237 related articles for article (PubMed ID: 18537624)
1. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
Sousa SF; Fernandes PA; Ramos MJ
Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics simulations on the critical states of the farnesyltransferase enzyme.
Sousa SF; Fernandes PA; Ramos MJ
Bioorg Med Chem; 2009 May; 17(9):3369-78. PubMed ID: 19369081
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Sebti SM; Hamilton AD
Expert Opin Investig Drugs; 2000 Dec; 9(12):2767-82. PubMed ID: 11093352
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.
Pan J; Yeung SC
Cancer Res; 2005 Oct; 65(20):9109-12. PubMed ID: 16230362
[TBL] [Abstract][Full Text] [Related]
8. Enzyme flexibility and the catalytic mechanism of farnesyltransferase: targeting the relation.
Sousa SF; Fernandes PA; Ramos MJ
J Phys Chem B; 2008 Jul; 112(29):8681-91. PubMed ID: 18572907
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
Shen M; Pan P; Li Y; Li D; Yu H; Hou T
Drug Discov Today; 2015 Feb; 20(2):267-76. PubMed ID: 25450772
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
Cox AD
Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
13. Lipid posttranslational modifications. Farnesyl transferase inhibitors.
Basso AD; Kirschmeier P; Bishop WR
J Lipid Res; 2006 Jan; 47(1):15-31. PubMed ID: 16278491
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation.
Bratt JM; Chang KY; Rabowsky M; Franzi LM; Ott SP; Filosto S; Goldkorn T; Arif M; Last JA; Kenyon NJ; Zeki AA
J Immunol; 2018 Jun; 200(11):3840-3856. PubMed ID: 29703864
[TBL] [Abstract][Full Text] [Related]
16. Evolving therapies: farnesyltransferase inhibitors.
Purcell WT; Donehower RC
Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
[TBL] [Abstract][Full Text] [Related]
17. A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics.
Porcu G; Wilson C; Di Giandomenico D; Ragnini-Wilson A
Mol Cancer; 2010 Jul; 9():197. PubMed ID: 20653956
[TBL] [Abstract][Full Text] [Related]
18. Computational studies of the farnesyltransferase ternary complex part I: substrate binding.
Cui G; Wang B; Merz KM
Biochemistry; 2005 Dec; 44(50):16513-23. PubMed ID: 16342942
[TBL] [Abstract][Full Text] [Related]
19. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
20. Measurement of the alpha-secondary kinetic isotope effect for the reaction catalyzed by mammalian protein farnesyltransferase.
Pais JE; Bowers KE; Fierke CA
J Am Chem Soc; 2006 Nov; 128(47):15086-7. PubMed ID: 17117849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
